Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis - Takeaways - MDSpire

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

  • By

  • Rodrigo R. de Sena

  • Kleyton de C Mesquita

  • Letícia F. Barroso

  • Paola B. E. Canabrava

  • Fernando Zanghelini

  • Ciro M. Gomes

  • March 18, 2026

  • 0 min

Share

  • 1

    Scheduled withdrawal of anti-interleukin therapy in psoriasis patients generally leads to inferior remission maintenance compared to ongoing treatment.

  • 2

    No reduction in adverse event rates was observed with planned withdrawal of anti-IL therapy in patients with psoriasis.

  • 3

    Bimekizumab and guselkumab withdrawal showed superior outcomes for PASI 90 endpoints compared to other anti-IL therapies.

  • 4

    Key considerations for biologic therapy withdrawal include drug half-life, relapse timing, and patient-specific factors.

  • 5

    This systematic review emphasizes the need for structured clinical pathways for managing anti-IL biologic therapy in psoriasis.

Original Source(s)

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

  • by Rodrigo R. de Sena, Kleyton de C Mesquita, Letícia F. Barroso, Paola B. E. Canabrava, Fernando Zanghelini, Ciro M. Gomes

  • March 18, 2026

Related Content

Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional study